Please login to the form below

Not currently logged in
Email:
Password:

Actinium appoints director of clinical operations

Gregory Bergonio brings experience from Novartis

New York, US-based Actinium Pharmaceuticals has appointed Gregory Bergonio as director of clinical operations, with particular responsibility for its Actimab-A phase II clinical trial programme.

Bergonio moves from Novartis, where he served as an expert clinical manager in the Swiss firm's oncology global development unit, specialising in acute myeloid leukaemia.

Prior to this, Bergonio held a number of clinical research management positions at Bausch & Lomb, OSI Eyetech, Forest Laboratories, i3 Research and Kern McNeil.

Sandesh Seth, Actinium's executive chairman, said: “We are very excited to welcome Greg to the clinical development team at Actinium.

“Greg's joining comes at an ideal time given our increased development efforts as a result of the Actimab-A phase II trial and Iomab-B pivotal phase III SIERRA trial.

“Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our current and planned clinical development efforts.”

5th January 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a team outstanding healthcare communications experts who provide innovative strategic evidence based solutions through scientific and commercial...

Latest intelligence

Medius Deal Watch
Deal Watch December 2016
Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up...
The Young Dementia Network - much more than a logo
Welcome to the second and final part of my two-part blog....
Patient-centred care innovation in dementia: a conversation with Neil Maiden
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators...

Infographics